Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Description

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.

Conditions

Cutaneous Lupus Erythematosus (CLE)

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.

A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Condition
Cutaneous Lupus Erythematosus (CLE)
Intervention / Treatment

-

Contacts and Locations

Phoenix

ARENSIA Exploratory Medicine, LLC, Phoenix, Arizona, United States, 85015

Fremont

Center for Dermatology Clinical Research Inc., Fremont, California, United States, 94538

La Jolla

UCSD Perlman Medical Offices, La Jolla, California, United States, 92037

Upland

Inland Rheumatology Clinical Trials Inc., Upland, California, United States, 91786

Aurora

University of Colorado, Barbara Davis Center, Center for Clinical Research, Aurora, Colorado, United States, 80045

New Haven

Yale Center for Clinical Investigation (YCCI), New Haven, Connecticut, United States, 06510

Clearwater

Clinical Research of West Florida, Inc., Clearwater, Florida, United States, 33765

Miami

Reliant Medical Research, Miami, Florida, United States, 33165

Orlando

HMD Research LLC, Orlando, Florida, United States, 32819

Atlanta

Emory University School of Medicine, Atlanta, Georgia, United States, 30303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Either fulfill European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) and/or have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time.
  • * Must have active CLE at screening and Day 1. Individuals with acute CLE (ACLE) must have involvement of 2 distinct body areas.
  • * Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A) score (excluding alopecia) of ≥ 8 and CLASI-A erythema score of ≥ 4 during screening and on Day 1. Individuals with SLE must have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥ 4 at screening.
  • * Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and individual willingness to undergo skin punch biopsy at 2 time points.
  • * Must have documented prior intolerance or inadequate response at any time (per investigator judgement) to protocol-specified treatments.
  • * Topical corticosteroids or topical calcineurin inhibitors.
  • * Oral corticosteroids.
  • * Any other nonbiologic standard-of-care therapy, including, but not limited to: chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil (MMF), leflunomide, dapsone, or methotrexate (MTX).
  • * Individuals willing to comply with all study visits and assessments.
  • * Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or localized acute CLE involving only 1 distinct body area at screening and Day 1.
  • * Have highly active SLE (including but not limited to lupus nephritis, neuropsychiatric SLE, and/or vasculitis).
  • * Presence of active skin conditions other than cutaneous lupus that may interfere with assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus).
  • * Meet protocol-specified infection or lab criteria.
  • * Any active infection that is clinically significant (per investigator judgment).
  • * Any history of clinically significant liver disease.
  • * Significant cardiovascular disease.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Gilead Sciences,

Gilead Study Director, STUDY_DIRECTOR, Gilead Sciences

Study Record Dates

2025-09